Sign In to Request a Protocol
Sign In to Request a Protocol

Survodutide (10 mg Vial) Protocol

  • Published March 13, 2026
  • Updated June 14, 2026
  • Table of Contents

Survodutide Overview

Survodutide is presented for general research and educational reference. This page provides general product information and research background. This information is for research and educational use only.
  • Product Information: TSurvodutide is supplied as a lyophilized research peptide intended for laboratory and educational applications.
  • Research Overview: Survodutide has been investigated in scientific research related to metabolic health and weight management.
  • General Information: Product information and availability may vary. For additional information, please contact us on Telegram.
  • Storage: Store according to the instructions provided on the product label or packaging.

Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist under development for obesity and metabolic liver disease. Clinical research has investigated its potential role in metabolic health and weight management. This educational overview is intended to provide general research information and should not be considered medical advice, treatment guidance, or usage instruction.

  • Related Research For additional research context and safety information, explore related compounds and formulations for comparison purposes only. These comparisons are intended for educational reference and should not be considered interchangeable products.
  • Overview & General Management Guide
Educational Guide for Proper Handling and Protocol

Standard / General Information

Administration is structured on a once-weekly assessment and implementation cycle, adhering strictly to established trial methodologies to observe progressive development over an extended duration.
WeekWEEKLY VALUETRACKING VALUEUNIT MEASUREMENT
Weeks 1–20.6 units600 units12 units (0.12 Vol)
Weeks 3–41.2 units1200 units24 units (0.24 Vol)
Weeks 5–61.8 units1800 units36 units (0.36 Vol)
Weeks 7–82.4 units2400 units48 units (0.48 Vol)
Weeks 9–103.6 units3600 units72 units (0.72 Vol)
Weeks 11–124.8 units4800 units96 units (0.96 Vol)
Week 13+6.0 units6000 units120 units (1.20 Vol)*

Note: The 6.0 units maintenance volume (120 units / 1.20 Vol) exceeds a standard 100‑unit (1 Vol) dispensing tool. Use a 1 Vol or 3 Vol Luer‑lock tool with appropriate laboratory needle, or apply as two separate applications.

Preparation Steps
  • 1 . Draw 2.0 Vol diluent with a sterile laboratory tool.
  • 2 . Introduce slowly down the container wall; avoid foaming.
  • 3 . Gently swirl/roll until dissolved (do not shake).
  • 4 . Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
  • Supplies Needed
  • Product Containers (Survodutide, 10 mg each):
  • 4 weeks (28 doses at ~0.67–1.0 mg/day): 2 vials
  • 6 weeks (42 doses): 3 vials
  • 8 weeks (56 doses): 3–4 vials
  • U‑100 Laboratory Tools or 1 mL Luer‑lock Dispensing Tools:
  • Per week: 1 unit (once weekly)
  • 8 weeks: 8 units
  • 12 weeks: 12 units
  • Diluent Solution (10 mL bottles): Use 2.0 Vol per container for preparation.
  • 8 weeks (2 units): 4 Vol → 1 × 10 mL bottle
  • 12 weeks (4 units): 8 Vol → 1 × 10 mL bottle
  • 16 weeks (7 units): 14 Vol → 2 × 10 mL bottles
  • Alcohol Swabs: One for the container top + one for the application area each week
  • Per week: 2 swabs
  • 8 weeks: 16 swabs
  • 12 weeks: 24 swabs
  • 16 weeks: 32 swabs → recommend 1 × 100‑count box
  • Protocol Overview
Concise summary of the once‑weekly regimen.
  • Goal: Support research parameters and metabolic evaluation metrics.
  • Schedule: Weekly applications for 12–16 weeks (or longer as studied in baseline trials).
  • Value Range: 0.6–6.0 units weekly with gradual titration over 10–12 weeks.
  • Preparation: 2.0 Vol per 10 mg container (5 mg/Vol) for accurate unit measurements.
  • Storage: Lyophilized; prepared items refrigerated; protect from light and avoid temperature fluctuations.
  • Evaluation Protocol
Suggested weekly progressive approach based on clinical trial designs.
  • Start: 0.6 units weekly; increase by 0.6 units every 2 weeks as tolerated.
  • Target: 4.8–6.0 units weekly by weeks 11–13.
  • Frequency: Once per week (standard application).
  • Cycle Length: 12–16 weeks minimum; baseline trials extend to 48–72 weeks.
  • Timing: Same day each week; rotate application areas.
  • Storage Instructions
Proper storage preserves product quality.
  • Lyophilized: Store at ≤−20 °C (≤−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Prepared/Solution: Refrigerate at 2–8 °C (35.6–46.4 °F); protect from light and avoid repeated freeze–thaw cycles.
  • Allow containers to reach room temperature before opening to reduce condensation uptake.
  • Important Notes
Practical considerations for consistency and safety.
  • Use new sterile laboratory tools; dispose of them in a proper sharps or disposal container.
  • Rotate application areas (abdomen, thighs, upper arms) to reduce local irritation.
  • Apply slowly; wait a few seconds before withdrawing the application tool.
  • Document weekly protocol values, application areas, and any tolerability observations.
  • For application values exceeding 100 units (1.0 Vol), consider using a 1 mL Luer‑lock tool or splitting into two separate applications.
  • How This Works
Survodutide is a dual agonist that activates both GLP‑1 and glucagon receptors. The GLP‑1 component enhances satiety and improves baseline glycemic tracking, while the glucagon component increases energy expenditure and promotes hepatic lipid oxidation pathways. This dual mechanism is hypothesized to provide additive or synergistic effects on metabolic markers and overall profiling metrics beyond GLP‑1 activation alone. In phase 2 evaluations, survodutide demonstrated substantial progressive improvements alongside optimized tracking in liver enzyme markers.
  • Potential Evaluation Metrics & Observations​
Observations from scientific literature.
  • Progressive change metrics of 12.5–14.9% (vs placebo) over 46 weeks in phase 2 metabolic profile evaluations.
  • Improvements in liver‑related biomarkers in research populations focused on hepatic profiling.
  • Meta‑analysis confirms consistent efficacy and progression across multiple randomized controlled evaluations.
  • Observed tracking effects are primarily gastrointestinal: nausea, vomiting, diarrhea, and constipation (most common during initial value escalation).
  • Gradual titration helps mitigate these baseline tolerability issues.
  • Routine & Optimization Factors
Complementary strategies for best outcomes.
  • Pair with a balanced, protein‑forward diet tailored to energy needs; baseline activators can reduce appetite significantly.
  • Combine resistance training and aerobic activity to preserve lean mass during overall progress tracking.
  • Stay well hydrated, especially if experiencing GI tolerability variations.
  • Prioritize sleep and stress management to support metabolic health and protocol adherence.
  • Application Technique
General guidance from established best‑practice resources.
  • Clean the container top and the application area with alcohol; allow to dry.
  • Pinch the target area; insert the application tool at a 45–90° angle into the designated tissue area.
  • Maintain a steady, controlled approach; introduce the solution slowly and systematically.
  • Rotate application areas systematically (abdomen, thighs, upper arms) to avoid localized tissue fatigue or irritation.
  • Important Note
This content is intended for instructional and educational purposes only and does not constitute professional advice, evaluation, or specific protocols.
  • References

PubMed

— Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
More Info

Current Pharmaceutical Design (PubMed)

— Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract
More Info

PMC

— Utilizing developmentally essential secreted peptides such as Thymosin Beta-4 for regenerative therapies
More Info

Annals of the New York Academy of Sciences (PubMed)

— Thymosin beta 4 and wound healing: new ideas
More Info

PMC

— Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review
More Info

Johns Hopkins Arthritis Center

— How to give a subcutaneous injection
More Info

PMC

— Subcutaneous drug delivery review: pharmacologic considerations
More Info

ASIPP / Alternative Therapies in Health and Medicine

— Intra-articular injection of BPC-157 for multiple types of knee pain
More Info

A4M

— Thymosin Beta-4 professional monograph
More Info

PubMed

— Detection of thymosin beta-4 and related peptides in sport drug testing
More Info

Journal of Physiology and Pharmacology (PubMed)

— BPC-157 activity at very low doses without toxicity in animal studies
More Info

Expert Opinion on Biological Therapy (PubMed)

— Thymosin beta-4 and its role in wound healing
More Info

CDC

— Vaccine administration: subcutaneous route (angle/site; no aspiration)
More Info

NCBI Bookshelf

— Best practices for injection (asepsis, preparation, and administration)
More Info

Contact on Telegram Peptides

— BPC-157 + TB-500 (10 mg blend) product page (quality and batch documentation)
More Info

Vitality Labs provides general product information for educational reference. For product-specific details or availability, please contact us on Telegram.

Protocols

  • Single Peptides
  • Peptide Blends
  • Peptide Stacks
  • Research Information Calculator

Learn

  • Blog
  • Beginner's Guide
  • Storage Guide
  • Syringe & Measurement Guide
  • Glossary
  • FAQ

Company

  • About Us
  • Editorial Policy
  • Contact Us

Stay Updated

For product-specific details or availability, please contact us on Telegram.

Contact on Telegram

Important Disclaimer: All information provided on Vitality Labs is for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new research protocol.

© 2026 Vitality Labs. All rights reserved.

  • Privacy Policy
  • Terms of Service
  • Cookie Policy
  • Disclaimer